ASCO 2018
Chicago—Of the estimated 40,000 men in the United States with nonmetastatic castration-resistant prostate cancer ...
Chicago—Researchers in California conducted a study to compare 10-year treatment outcomes of radical prostatectomy ...
Chicago—Results from a previous study of patients with metastatic castration-resistant prostate cancer (mCRPC) ...
AFT-19: A Randomized Phase 3 Study in Patients with High Risk Biochemically Relapsed Prostate Cancer
Chicago—There is a high risk for the development of metastatic disease and prostate cancer-related mortality in ...
Chicago—Results from recent studies have demonstrated the high frequency with which metastatic prostate cancer can ...
Chicago—The current standard of care in patients with very high risk prostate cancer is radiotherapy and 18 to 28 ...
Chicago—Androgen signaling is not entirely suppressed with androgen deprivation therapy (ADT) with GnRH analogs. ...
Chicago—There is no evidence that the risk of prostate cancer is increased with testosterone treatment in hypogonadal ...
Chicago—There are few available data on disease-related complications such a bone fractures and urinary obstruction ...
Chicago—Results of the TOAD trial demonstrated that in progressive or relapsed prostate cancer patients after radical ...
Chicago—Sipuleucel-T (sip-T) is an autologous cellular immunotherapy approved in the United States for patients with ...
Chicago—Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen (PSA) ...
Chicago—Evaluation of treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) is ...
Chicago—Clinical decisions as well as drug development for prostate cancer are facilitated with intermediate clinical ...
Chicago—During a poster session at the ASCO 2018 Annual Meeting, Paul Sargos, MD, of the Institut Bergonié, Bordeaux, ...
Chicago—In the SPARTAN trial, men with nonmetastatic castration-resistant prostate cancer (nmCRPC) were treated with ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.